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treatment”). Cost per STP in 2001 is lower for tolterodine
(5523L. (€2.85)) than oxybutynin (17265L. (€8.92)). The
“no treatment” group demonstrated the highest non-drug
costs while providing no efficacy.
CONCLUSION: This economic model demonstrates that
tolterodine is more cost-effective than oxybutynin in
treating unstable bladder as measured by cost per suc-
cessfully treated patient in Italy.
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OBJECTIVES: Urinary incontinence and overactive blad-
der disorders are not recognized as significant issues for
employed populations. Perceived as a problem for women
over 50, and frequently undiagnosed, these conditions
may have undetected effects on employee health costs and
productivity. Using a large, longitudinal, multi-employer
health-care database this investigation examined inci-
dence and benefit use by employees who had a diagnosis
of urinary incontinence or overactive bladder disorder
(OAB).
METHODS: OAB was defined by ICD9 codes 595, 596
and 788. Incidence was estimated from a medical claims
database of 230,000 employees. Excess benefit costs were
derived from a subset (n  36,777) with four-years of
medical, absence, disability, and workers-compensation
(WC) data. Using a censored regression model to control
for differences in demographics, job and health charac-
teristics expected incremental-benefit costs for OAB were
calculated.
RESULTS: 2.58% of employees had OAB. Employees
with OAB were significantly (p  .01) older and more
likely to be female. Employees with OAB had significantly
(p  .001) higher costs for all benefits except WC (*p 
.19) and had a greater likelihood of filing disability claims.
Controlling other factors, OAB employees had higher
costs for medical (diff  $995), sick leave (diff  $151),
STD (diff  $148), LTD (diff  $76), and *WC (diff 
$178). Total difference was $1,548 per OAB employee.
Where individual productivity data were available, em-
ployees with OAB produced 5% fewer units annually, al-
though this is not statistically significant (p  .34).
CONCULSIONS: OAB was detected in one in every 40
employees. Employees with OAB were higher users of
health-related benefits, more costly overall, and absent
more frequently. As such, OAB may be a hidden source
of health costs for employers. More research needs to be
done to determine what portion of OAB-associated costs
can be avoided through appropriate treatment.
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OBJECTIVE: The aim of this study was to compare the
costs, efficacy and safety of basiliximab (Simulect) versus
Thymoglobuline in the treatment of renal transplant in-
duction.
METHODS: We carried out an economic evaluation
based on the data from clinical trial CHI-F-02. A total of
100 patients, fifty in each group, were recruited from
nine sites across France. We estimated the direct medical
costs of two strategies of renal transplant induction ther-
apy incurred over six months in a piggy-back approach.
Direct medical costs covered medications, hospital stays,
dialysis, consultations and examinations not scheduled
by the protocol. As both treatments offer the same effi-
cacy, we ran a cost-minimisation study. The cost of care
was analysed from a hospital perspective. Wilcoxon rank
sum tests were performed to analyse the cost differences
between the two strategies.
RESULTS: The study showed a significant reduction in
the duration of initial hospital stay in the Simulect arm,
as well as a significant reduction in the number of infec-
tious episodes. Therefore, although the average cost of
treatment with Simulect appears slightly higher than the
cost with Thymoglobuline (2964 versus 2298 Euros), the
cost of initial hospitalization is significantly lower in the
Simulect arm (10 900 versus 11 967 Euros, p  0.02).
Furthermore the mean cost of infectious episodes is sig-
nificantly lower in the Simulect arm (1056 versus 1790
Euros, p  .03). CMV infection accounts for 30% of this
cost in the Simulect arm and 53% in the Thymoglobuline
arm with a significantly different cost (p  0.01).
CONCLUSION: In terms of direct medical costs, this
study shows a saving of 1067 Euros per patient in the
Simulect arm, which compensates for the initial higher
price of this immunosuppressive drug.
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OBJECTIVE: A significant portion of the population en-
dures economic, physical, and emotional burdens from
overactive bladder (OAB). OAB, with and without incon-
tinence, causes strong, sudden, and unpredictable urges
to urinate. People with OAB may be at greater risk for
urinary tract infections (UTIs), falls and fractures, and in-
creased medical visits, but to date, the extent to which
consequent treatment costs are associated with OAB is
unknown.
METHODS: The National Overactive BLadder Evalua-
tion (NOBLE) Program included a US survey of 5204 En-
glish-speaking adults over 18 years to estimate the preva-
lence of OAB. All OAB cases and age- and gender-matched
controls were sent a follow-up questionnaire to assess the
occurrence of UTIs, falls, and medical visits in the past
year. A total of 397 (46%) patients and 522 (57%) con-
trols returned the questionnaires. The non-response rate of
patients and controls did not differ with age, gender, edu-
cational status, diabetes, congestive heart failure, or self-
rated health status. UTIs and physician visits were analy-
sed using multivariate regression models, controlling for
age, gender, race, education, marital status, births, self-
reported health status, and presence of diabetes and con-
gestive heart failure.
RESULTS: People with OAB averaged 20% more physi-
cian visits (P  .001), had 57% more UTIs in the last
year (P  .001), and had over twice the odds of being in-
jured in a fall than people without OAB (OR  2.26;
95% CI 1.46, 3.51; P  .001). Sensitivity analyses (re-
moving 5% of the outliers as identified with Cook’s dis-
tance) indicated that the effects were robust. Cost esti-
mates associated with OAB in the year 2000 were
approximately $1.37 billion and $273 million US dollars
for UTIs and falls/broken bones, respectively.
CONCLUSIONS: OAB increases the risk for UTIs and
fall injuries and results in more physician visits. OAB-
related costs were over $1.6 billion US dollars in 2000.
Effective treatment would likely reduce these costs.
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OBJECTIVE: Despite the significant impact of urinary in-
continence (UI) on patient’s Quality of Life (QoL), there is a
lack of internationally validated instruments to assess QoL.
METHODS: CONTILIFE® is a specific UI 28-item QoL
scale, measuring six dimensions: Daily Activities (DA);
Effort Activities (EA); Self Image (SI); Emotional Impact
(EI); Sexuality (SX); Well Being (WB). QoL was assessed
at inclusion and after a four-week treatment period in
505 UI women from Belgium, Denmark, France, Germany,
the Netherlands and the UK (mean age: 51years 
 11; mean
number of urinary leakages over the past 7 days: 16 
 14).
The validity, reliability and sensitivity to change over time
were assessed according to standard guidelines. In addition,
Rasch modeling and Multiple Factor Analysis (MFA) were
used to assess the cross-cultural equivalence and the stability
over time of the CONTILIFE.
RESULTS: According to the number of urinary leakages
(NUL) the clinical validity was very good. All scores were
highly correlated (p  .007) with the NUL. The QoL
scores were responsive to NUL improvement (effect sizes 
0.4), except for the SX and WB dimensions. The con-
struct validity was good (Chronbach alpha  0.7), with
scaling success over 90% in all dimensions except DA
(convergent validity 86%). The severity of the items was
consistent across countries according to Rasch, but MFA
showed a limited equivalence of the underlying construct
across countries. Nevertheless, the stability of the scale’s
structure over the four-week period was excellent.
CONCLUSION: CONTILIFE demonstrated its overall
validity, reliability and sensitivity to change over time in
this international sample. These good properties allow re-
searchers to include this QoL measure as an endpoint in
international clinical trials dealing with female UI.
MENTAL HEALTH
PMH1
RIGOROUS CRITERIA FOR TREATMENT 
RESPONSE DIFFERENTIATED EFFICACY OF 
OLANZAPINE VERSUS HALOPERIDOL IN 
PATIENTS WITH SCHIZOPHRENIA
Kinon BJ, Zhao Z, Barber BL, Gilmore JA
Lilly Research Laboratories, Indianapolis, IN, USA
OBJECTIVE: To demonstrate that the progressive eleva-
tion of the threshold for definition of treatment response
elucidates the greater likelihood of patients with schizo-
phrenia responding to the novel antipsychotic olanzapine
(OLZ) as compared to haloperidol (HAL).
METHODS: Data was analyzed post-hoc from the acute
phase of a large, prospective, randomized (OLZ versus
HAL, mean modal dose  13.2 versus 11.8 mg/day, re-
spectively), double-blind trial, conducted in 17 countries
with 1996 patients who met the DSM-III-R criteria for
schizophrenia, schizophreniform disorder, or schizoaffec-
tive disorder. The cumulative proportion of patients
achieving a priori defined response criteria at each of
three thresholds was determined. Thresholds for clinical
improvement were 20% or greater, 40% or greater, and
65% or greater reduction in endpoint to baseline Brief
Psychiatric Rating Scale (BPRS) total scores. At each
week, chi-square tests were used to compare the propor-
tion of OLZ-treated patients versus the proportion of
